Evidence map›Paper›PMID 40041886›Full record

ArticleActa pharmaceutica Sinica. B2025

Drofenine as a Kv2.1 inhibitor alleviated AD-like pathology in mice through A

Jian Lu, Qian Zhou, Danyang Zhu, Hongkuan Song, Guojia Xie, Xuejian Zhao, Yujie Huang, Peng Cao, Jiaying Wang, Xu Shen

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jian LuSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Qian ZhouJiangsu Provincial Medical Innovation Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Danyang ZhuSchool of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Hongkuan SongSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Guojia XieSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Xuejian ZhaoSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yujie HuangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Peng CaoJiangsu Provincial Medical Innovation Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jiaying WangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Xu ShenSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease with clinical hallmarks of progressive cognitive impairment. Synergistic effects of the A

Indexed as

Alzheimer's diseaseAβ-Tau cascade reactionCognitive impairmentDrofenineKv2.1 channelMicrogliaNLRP3 inflammasomePotassium efflux

Identifiers

PMID40041886
PMCPMC11873626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.